AstraZeneca_NNP Annual_JJ Report_NNP and_CC 96_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 7_CD PROPERTY_NN ,_, PLANT_NNP AND_CC EQUIPMENT_NNP Assets_NNPS in_IN Total_NNP Land_NNP and_CC Plant_NNP and_CC course_NN of_IN tangible_JJ buildings_NNS equipment_NN construction_NN assets_NNS $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Cost_NN At_IN 1_CD January_NNP 2003_CD 3,145_CD 6,612_CD 1,298_CD 11,055_CD Capital_NN expenditure_NN 67 215 964_CD 1,246_CD Transfer_NNP of_IN assets_NNS into_IN use_NN 510_CD 915_CD 1,425_CD Disposals_NNS and_CC other_JJ movements_NNS 42_CD 667_CD 22_CD 731_CD Exchange_NNP adjustments_NNS 448 906 133_CD 1,487_CD At_IN 31_CD December_NNP 2003_CD 4,128_CD 7,981_CD 948_CD 13,057_CD Capital_NN expenditure_NN 17 205 851_CD 1,073_CD Transfer_NNP of_IN assets_NNS into_IN use_NN 430_CD 641_CD 1,071_CD Disposals_NNS and_CC other_JJ movements_NNS 55_CD 335_CD 6_CD 396_CD Exchange_NNP adjustments_NNS 281_CD 590_CD 45_CD 916_CD At_IN 31_CD December_NNP 2004_CD 4,801_CD 9,082_CD 767_CD 14,650_CD Capital_NN expenditure_NN 13 150 669 832_CD Transfer_NNP of_IN assets_NNS into_IN use_NN 257 594 851_CD Disposals_NNS and_CC other_JJ movements_NNS 99_CD 820_CD 14_CD 933_CD Exchange_NNP adjustments_NNS 482_CD 971_CD 91_CD 1,544_CD At_IN 31_CD December_NNP 2005_CD 4,490_CD 8,035_CD 480_CD 13,005_CD Depreciation_NN At_IN 1_CD January_NNP 2003_CD 895_CD 3,555_CD 4,450_CD Charge_NNP for_IN year_NN 150 840 990_CD Disposals_NNS and_CC other_JJ movements_NNS 35 553 588_CD Exchange_NNP adjustments_NNS 129 529 658_CD At_IN 31_CD December_NNP 2003_CD 1,139_CD 4,371_CD 5,510_CD Charge_NNP for_IN year_NN 172 749 921_CD Impairment_NNP 31_CD 31_CD Disposals_NNS and_CC other_JJ movements_NNS 37 302 339_CD Exchange_NNP adjustments_NNS 86 344 430_CD At_IN 31_CD December_NNP 2004_CD 1,360_CD 5,193_CD 6,553_CD Charge_NNP for_IN year_NN 166 799 965_CD Impairment_NNP 90_CD 90_CD Disposals_NNS and_CC other_JJ movements_NNS 53 794 847_CD Exchange_NNP adjustments_NNS 153 588 741_CD At_IN 31_CD December_NNP 2005_CD 1,320_CD 4,700_CD 6,020_CD Net_JJ book_NN value_NN At_IN 31_CD December_NNP 2003_CD 2,989_CD 3,610_CD 948_CD 7,547_CD At_IN 31_CD December_NNP 2004_CD 3,441_CD 3,889_CD 767_CD 8,097_CD At_IN 31_CD December_NNP 2005_CD 3,170_CD 3,335_CD 480_CD 6,985_CD Impairment_NN charges_NNS in_IN 2005_CD relate_VBP to_TO the_DT write-down_NN of_IN assets_NNS associated_VBN with_IN capacity_NN reviews_NNS at_IN manufacturing_VBG sites_NNS ,_, primarily_RB in_IN the_DT UK_NNP and_CC France_NNP ._.
These_DT were_VBD recognized_VBN in_IN cost_NN of_IN sales_NNS in_IN the_DT income_NN statement_NN ._.
The_DT impairment_NN charge_NN in_IN 2004_CD was_VBD made_VBN to_TO write_VB off_RP assets_NNS associated_VBN with_IN Iressa_NNP ._.
This_DT was_VBD recognized_VBN in_IN cost_NN of_IN sales_NNS in_IN the_DT income_NN statement_NN ._.
Capital_NNP expenditure_NN in_IN the_DT year_NN of_IN $_$ 832m_CD 2004_CD $_$ 1,073_CD m_NN ,_, 2003_CD $_$ 1,246_CD m_NN did_VBD not_RB include_VB any_DT capitalized_VBN finance_NN leases_NNS 2004_CD $_$ nil_CD ,_, 2003_CD $_$ nil_JJ ._.
